European PRAC starts review of Zynteglo (betibeglogene autotemcel)

The European PRAC has started a safety review of Zynteglo, a gene therapy authorised to treat beta thalassaemia, following a case of acute myeloid leukaemia reported in a patient treated with a related investigational medicine which uses the same viral vector.

Source:

European Medicines Agency